C4 Therapeutics Inc.
CCCC | NASDAQ
$3.33
+$0.03 (+0.91%)
Sep 22, 2026, 2:06 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -1.50 | -2.37 | -2.12 | -2.25 | -17.69 | -21.51 |
PEG Ratio | 0.09 | 0.05 | -1.11 | -0.05 | -0.97 | -0.23 |
PS Ratio | 4.40 | 7.02 | 13.51 | 9.27 | 32.38 | 42.98 |
PB Ratio | 0.62 | 1.16 | 1.14 | 1 | 3.81 | 5.08 |
P/FCF Ratio | -1.59 | -3.82 | -2.58 | -2.59 | -16.80 | -21.01 |
P/OCF Ratio | -1.60 | -3.83 | -2.63 | -2.72 | -17.05 | -21.21 |
OCF/S Ratio | -274.55 | -183.11 | -514.73 | -340.68 | -189.94 | -202.59 |
Debt / Equity Ratio | 0.23 | 0.30 | 0.29 | 0.30 | 0.11 | 0.08 |
Quick Ratio | 7.81 | 5.71 | 6.34 | 7.82 | 6.36 | 8.69 |
Current Ratio | 7.81 | 5.71 | 6.34 | 6.46 | 6.36 | 8.69 |
Asset Turnover | 0.10 | 0.10 | 0.06 | 0.07 | 0.09 | 0.08 |
Interest Coverage | n/a | n/a | -101.26 | -58.45 | -38.29 | -49.19 |
Return on Equity | -40.92% | -48.76% | -53.83% | -44.32% | -21.53% | -23.62% |
Return on Assets | -29.24% | -30.12% | -35.20% | -29.75% | -16.55% | -16.58% |
Return on Invested Capital | -31.43% | -38.56% | -41.02% | -32.94% | -17.98% | -16.92% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 77.81% | 100% | 62.72% | 100% | 100% | -136.30% |
Net Profit Margin | -292.08% | -295.96% | -638.34% | -412.19% | -183.23% | -199.83% |
Pretax Profit Margin | -291.74% | -295.60% | -632.17% | -412.19% | -183.23% | -197.95% |
Operating Profit Margin | -290.68% | -336.15% | -669.84% | -416.56% | -179.39% | -182.10% |
FCF Margin | -276.24% | -183.61% | -522.96% | -358.36% | -192.73% | -204.55% |
EBITDA Margin | -286.29% | -290.49% | -588.28% | -399.68% | -175.29% | -177.23% |
Add to Watchlist
Select watchlists to add or remove CCCC